Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
What is your preferred empiric antibiotic escalation for a patient with chorioamnionitis with worsening signs of sepsis on single agent cefoxitin?
Related Questions
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
What is the best approach to determine whether antiviral post-exposure prophylaxis for influenza is appropriate in an elderly immunocompromised patient who has been vaccinated?
How would you manage a patient with brucella melitensis abscess in whom surgery was initially deferred, developed worsening lower extremity numbness and weakness and MRI findings despite 1 month of combination therapy with ceftriaxone, rifampin, and doxycycline, and who is now readmitted to hospital following surgical washout?
Is there a specific criteria that you use to determine if a patient with respiratory symptoms should have a multiplex respiratory test performed?
What criteria should be used to determine the timing of placing central venous access or cardiac devices in patients with Staphylococcus lugdunensis infective endocarditis, considering the skip phenomenon?
Do you prefer a specific clinical scoring system to determine if a patient needs to be tested for Group A Streptococcal pharyngitis?
What do you think about chronic suppressive therapy for HSV-2 in a patient with positive antibodies but no prior clinical outbreak?
Do you recommend chronic oral suppressive antibiotics after initial intensive treatment of 6-8 weeks in patients with culture-negative prosthetic joint or bone infections with retained hardware?
Do you routinely recommend adjunctive rifampin therapy for the management of Staphylococcus aureus native vertebral osteomyelitis?
For a patient on appropriate treatment for invasive aspergillosis, how do you determine if and when it is acceptable to reintroduce a TNF inhibitor that likely contributed to their acquisition of the infection but is considered essential for control of their inflammatory condition?
